Discovery of Precision Oncology Drugs
NTRC provides in vitro drug discovery services focused on Precision Medicine. We help you to find the informed route to the clinic. Information can be found at www.oncolines.com
Computational Models of Synergy for Efficient Combination Screening
The poster presents three models to predict synergy based on the profiling of single agents in a cancer cell line panel. The model predictions for the PARP inhibitor niraparib are compared to the outcome of a large and unbiased combination screen.